Status:
RECRUITING
Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT
Lead Sponsor:
Peking University People's Hospital
Conditions:
Myelodysplastic Syndrome
Acute Leukemia
Eligibility:
All Genders
12-65 years
Phase:
PHASE2
Brief Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is regarded as a curative therapy for a variety of hematological malignancies and nonmalignant diseases. However, donor limitations have ...
Eligibility Criteria
Inclusion
- Patients with AL - CR and/or myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation for the first time;
- No gender limit, aged 12 - 65 years;
- Planned haploidentical donor transplantation, excluding transplantation from maternal and collateral donors;
- Eastern Cooperative Oncology Group (ECOG) performance status score≤3 points;
- Baseline organ function tests meet the following criteria:
- (1) Left ventricular ejection fraction (LVEF) \> 55%; (2) Serum creatinine ≤ 1.5 × upper limit of normal (ULN).
Exclusion
- Patients with severe dysfunction of brain, heart, kidney or liver;
- Those in refractory malignant status;
- Patients with other malignancies requiring treatment;
- Presence of uncontrolled severe active infection clinically;
- Expected survival period of less than 3 months;
- History of severe allergic reactions;
- Pregnant or breastfeeding women; (8)Presence of any condition deemed by the investigator as unsuitable for study enrollment.
Key Trial Info
Start Date :
May 21 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06984536
Start Date
May 21 2025
End Date
July 31 2026
Last Update
July 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People'S Hospital
Beijing, China